NCT04084431
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have had previous WBRT or prophylactic whole brain irradiation (PCI)
Exclusions: Patients who are eligible for SRS or surgery on brain metastases as a treatment alternative
https://ClinicalTrials.gov/show/NCT04084431